Markets
Borrow
Earn
Invest
Private
Security
Newsroom
More
Log In
Sign Up
Markets
Market Overview
Indices and commodities.
Digital Credit
Bitcoin treasury preferreds.
AI Stocks
The artificial intelligence theme.
Bitcoin Treasuries
Companies holding bitcoin.
Economy
Sectors, global markets and rates.
Popular Portfolios
13F filings, smart money.
Borrow
Borrow
Borrow USDT or USDC against your BTC without giving it up.
ReFi
Switch your bitcoin-backed loan and pay less interest.
Earn
Carry Trade
Borrow, invest, keep the spread.
Stock Dividends
Dividends from tokenized equities.
Invest
Private
Security
Newsroom
More
Company
About Us
Our leadership team, mission, and investors.
Whitepaper
Vision, purpose, and architecture behind Roxom.
Legal
Terms, privacy, and disclosures.
Resources
Help Center
Guides, FAQs & support.
Rulebook
Trading logic, platform rules, and fundamentals.
API Docs
Connect, authenticate, and build with our API.
Status
Current platform health and incidents.
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
1 BTC
=
- USD
BTC
SATS
Loading market data...
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
NC
NuCana plc American Depositary Share
NCNA
Mkt Cap
$4.1M
Volume
46.04K
Next Earnings
November 12th
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
NC
NCNA
NC
NuCana plc American Depositary Share
NCNA
News
·
NuCana Appoints Theresa Bruce as Chief Operating Officer
Mkt Cap
$4.2M
Volume
46.04K
Next Earnings
November 12th
Chart
Financials
Earnings
News
About
Insider
Filings
NuCana Appoints Theresa Bruce as Chief Operating Officer
NuCana plc announced the appointment of Theresa Bruce as Chief Operating Officer effective January 1, 2026. Bruce brings over 25 years of experience in oncology R&D and clinical operations. The appointment comes as NuCana plans to advance its pipeline with anticipated data readouts in 2026 for NUC-7738 and further characterization of NUC-3373, with cash runway extending into 2029.
GlobeNewswire Inc. · Jan 6, 2026
NuCana Presents Latest Data Demonstrating Clinical Activity and Favorable Safety for NUC-7738 in Patients with PD-1-Resistant Melanoma
NuCana presented clinical data at ESMO Immuno-Oncology Congress demonstrating promising results for NUC-7738 in treating PD-1 inhibitor-resistant metastatic melanoma, with two partial responses and seven cases of stable disease.
GlobeNewswire Inc. · Dec 10, 2025
NuCana Announces Grant of Composition-of-Matter Patent for NUC-7738 in China
NuCana received a patent from China's National Intellectual Property Administration for NUC-7738, a novel anti-cancer agent currently in Phase 1/2 clinical trials, strengthening its global intellectual property strategy.
GlobeNewswire Inc. · Nov 5, 2025
NuCana to Present Data on NUC-7738’s Synergy with PD-1 Inhibitors at the ESMO Congress 2025
NuCana will present research on NUC-7738, a novel anti-cancer agent, at the ESMO Congress 2025 in Berlin, highlighting potential synergies between the drug and PD-1 inhibition in renal cell cancer.
GlobeNewswire Inc. · Sep 3, 2025
NuCana Reports Second Quarter 2024 Financial Results and Provides Business Update
NuCana reported a net loss of £7.0 million for Q2 2024 and had £11.6 million in cash as of June 30, 2024. The company is advancing its clinical programs, including NUC-3373 and NUC-7738, and expects to announce data readouts in the second half of 2024.
GlobeNewswire Inc. · Aug 15, 2024
NuCana to Present at the Jefferies Global Healthcare Conference
NEW YORK, May 30, 2024 (GLOBE NEWSWIRE) -- NuCana plc (Nasdaq: NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will present and host one-on-one meetings at the Jefferies Global Healthcare Conference.
GlobeNewswire Inc. · May 30, 2024
NuCana to Present at TD Cowen’s 5th Annual Oncology Innovation Summit
EDINBURGH, United Kingdom, May 21, 2024 (GLOBE NEWSWIRE) -- NuCana plc (Nasdaq: NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will present at TD Cowen’s 5th Annual Oncology Innovation Summit: Insights for ASCO & EHA.
GlobeNewswire Inc. · May 21, 2024
NuCana Reports First Quarter 2024 Financial Results and Provides Business Update
Key Data Readouts on Track for All Programs in 2024
GlobeNewswire Inc. · May 16, 2024
NuCana Regains Compliance with Nasdaq Minimum Bid Price Requirement
EDINBURGH, United Kingdom, May 01, 2024 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA), (“NuCana” or the “Company”), announced that it has received a written notification (the “Notification Letter”) from the Listing Qualifications Department of the Nasdaq Stock Market, LLC (“Nasdaq”) informing the Company that it has regained compliance with the minimum bid price requirement for continued listing set forth in Nasdaq Listing Rule 5450(a)(1) (the “Minimum Bid Price Requirement”) and the matter is closed.
GlobeNewswire Inc. · May 1, 2024
NuCana Presents Data at the AACR 2024 Annual Meeting Highlighting the Ability of NUC-7738 to Profoundly Alter Tumor Biology in a Paired Biopsy Clinical Study
NUC-7738 Reprograms Cancer Cell Lipid Metabolism to Make Tumors Less Aggressive and Promote Cancer Cell Death
GlobeNewswire Inc. · Apr 9, 2024
Holdings
Open Orders (0)
Positions (0)
Order History
Dividends
Transfers
Log In
to start trading
NC
NCNA
NuCana plc American Depositary Share
Buy
Sell
Market
Limit
Soon
NCNA
25%
50%
75%
Max
Pay with
—
Start Trading
Available Balance
0.00
Your Position
You don't own any NCNA yet.
Related Tickers
Earnings